Prime Minister Justin Trudeau announced $175 million for a Vancouver biotech company, AbCellera Biologics Inc., which has identified antibodies that could be used to create treatments or a vaccine, in an May 3, 2020 story. (Photo by THE CANADIAN PRESS)

Vancouver biotech company discovering antibodies for COVID-19 treatment

Prime Minister Justin Trudeau announced $175 million federal funding for AbCellera

There may be another valuable shield in the fight against COVID-19, and the head of a Vancouver biotech firm says it could buy time as researchers race to develop a vaccine.

Carl Hansen, CEO of AbCellera Biologics Inc., said a drug built with antibodies could be used to protect vulnerable populations until a vaccine is more widely available.

The antibodies would give patients all the molecular material they need to fight the disease instead of depending on their bodies to develop their own as with a vaccine, giving them faster protection, he said.

“A prophylactic antibody could well be more effective than a vaccine,” he said.

On Sunday, Prime Minister Justin Trudeau announced $175 million federal funding for AbCellera to support its work in discovering those antibodies using a high-tech platform.

The funding also supports the company’s plans to build technology and manufacturing infrastructure for antibody therapies against future pandemic threats.

In partnership with pharmaceutical giant Eli Lilly, AbCellera is among a handful of companies on track for clinical trials this summer.

“There are many groups trying to rapidly develop vaccines for COVID-19 and vaccines are a very important part of the global response,” Hansen said.

“What we’re doing is different. What we’re doing is searching through an immune response that was generated from an actual infection and recovery in a patient and then finding that one antibody out of the literally millions that is best suited to stop the virus and that can be manufactured,” he said.

In 2012, Hansen said AbCellera recognized it could combine technologies from artificial intelligence, genomics, microfluidics and immunology to quickly search through natural immune systems to find antibodies that fight infection.

Two years ago, AbCellera began working with the Defense Advanced Research Projects Agency in the United States as part of a program to “radically accelerate” pandemic response, Hansen said. The company was working on simulations using its antibody-identifying technology when the COVID-19 pandemic struck.

“We quickly pivoted our efforts,” Hansen said.

Using blood samples from one of the first recovered COVID-19 patients in the United States on Feb. 25, AbCellera began screening millions of cells.

It narrowed down 500 unique human antibodies against the virus to a set of 24 that showed high promise of being therapeutic, he said.

“More recently we have further refined that set to a single antibody that is now being manufactured with the objective of having a first in-human trial start in July,” Hansen said.

What typically takes up to five years has been accelerated to less than four months, he said.

Vaccines and antibody-based prevention drugs work differently. With a vaccine, you inject a patient with a weakened virus or part of a virus to stimulate the immune system’s natural production of antibodies. With a prophylactic antibody, you insert the antibodies into the patient, Hansen said.

There are benefits and drawbacks. On one hand, prophylactics create more immediate protection because there’s no waiting period for the body to create its own antibodies. It’s also more broadly effective, because not all patients’ immune systems may be up to the task of producing their own antibodies.

On the other hand, a substantial number of antibodies must be administered to the patient in order to protect them.

“What that means is that the ability to manufacture hundreds of millions or even a billion doses of a vaccine is something well within the realm of possibility today. Making that many doses of antibodies is not,” he said.

That would mean giving the antibody to select groups of people at risk, such as health workers or the elderly, Hansen said.

The World Health Organization recommends that pharmacological treatment for COVID-19 should not be used outside of clinical trials.

On April 27, British Columbia’s COVID-19 therapeutics committee issued the same warning.

“There are no proven therapies for the prevention or treatment of COVID-19. All agents have the possibility of associated harm, and pharmaceutical supplies province-wide and nationally for many of the possible agents are severely limited,” it said.

For Hansen, research and development during the pandemic has not been business as usual.

“It’s not a race against our competitors nearly as much as it’s a race against the virus,” he said.

“What matters most is we get a therapy out there that works for patients and do so as quickly as possible.”

Amy Smart, The Canadian Press

Coronavirus

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Top cop calls video of Kelowna Mountie striking suspect ‘concerning’

A video allegedly shows a Kelowna Mountie striking a man several times

$173K to support Okanagan seniors amid pandemic

United Way announces more funding for frontline programs

Okanagan home sales increase over last month, still below 2019 numbers: OMREB

Sales, listings see increase over May’s numbers but dwindle in comparison to 2019

PPE donation reaches Central Okanagan Elizabeth Fry Society

Ending Violence Association of BC received a $20,000 donation for personal protective equipment

Small business grants available through Okanagan initiative

Susie and Bryan Gay launched ‘This Bag Helps’ to help fellow small business owners during the pandemic

B.C. records four new COVID-19 cases, Abbotsford hospital outbreak cleared

Four senior home outbreaks also declared over, eight still active

Princeton RCMP sergeant kills cougar threatening residential neighborhood

An RCMP officer shot and killed a cougar, close to a residential… Continue reading

Pilot project approved: Penticton to allow alcohol in outdoor spaces

For almost two hours, council debated the proposed pilot project, before eventually passing it 4-2

Drugs, machete found in truck with stolen plate driven by Salmon Arm man

Chase RCMP arrest driver and have vehicle towed

RCMP, coroner investigate murder-suicide on Salt Spring Island

Two dead, police say there is no risk to the public

About 30% of B.C. students return to schools as in-class teaching restarts amid pandemic

Education minister noted that in-class instruction remains optional

Trudeau avoids questions about anti-racism protesters dispersed for Trump photo-op

Prime minister says racism is an issue Canadians must tackle at home, too

B.C.’s Law Enforcement Torch Run for Special Olympics goes virtual

The annual event partnering RCMP with Special Olympians is dramatically altered by COVID-19

HERGOTT: Can you get money back if COVID-19 disrupts plans?

Paul Hergott is a personal injury lawyer based in West Kelowna

Most Read